SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently trending as investors debate whether the recent price decline represents an oversold opportunity or a long-term exhaustion of the project's potential. While some community members are actively dollar-cost averaging to lower their cost basis, others are voicing frustration over the persistent disconnect between the network's ongoing enterprise utility and the token's stagnant market performance.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community closely watches the Senate Banking Committee markup of the Clarity Act, which many believe will provide the regulatory framework necessary for institutional adoption and long-term utility growth. Investors remain divided between bullish expectations for upcoming payroll partnerships and partnerships with major tech entities, and skeptical voices warning of price volatility and consistent rejections at resistance levels.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing heightened market attention as investors debate its role as critical infrastructure versus concerns over its current tokenomics. Community discussions are heavily centered on the project's long-term utility in enabling RWA tokenization and its strategic integrations with institutional players like the DTCC.

BTQ Technologies Corp. engages in the business of post-quantum encryption. Its products include: QCIM, QSSN, OSS, QPoW, QRiNG. The company was founded by Nicolas Roussy Newton on Novemeber 23, 1983 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending as investors react to a flurry of recent activity, including the opening of a New York quantum hardware hub and key engineering hires, which have fueled speculation about potential commercial partnerships or an acquisition. The community is actively debating the company's long-term potential as a quantum security solution against the backdrop of its high volatility and the ongoing internal leadership drama, with many watching for any sign of a major commercial contract that could drive a significant price breakout.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is surging as investors react to positive autonomous trucking developments, including expanded logistics partnerships and increased analyst attention. The community is actively discussing a potential short squeeze driven by significant institutional ownership and anticipation of major milestones as the company scales its driverless technology.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and social media users heatedly debate the company's market behavior in relation to geopolitical developments and administration policy announcements. Community discussion is sharply polarized, focusing on skepticism regarding corporate and political transparency, the broader economic implications of current federal strategies, and the overall impact of public discourse on the stock's volatility.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum (HQ) is seeing intense volatility and massive volume spikes as traders track its role as a potential 'Microsoft of quantum computing' software, bolstered by strategic investments from industry leaders like IonQ and Dell. The community is heavily focused on the stock's low public float and recent de-SPAC status, fueling speculation about a potential short squeeze even as some investors express caution regarding the company's valuation and long-term patent moat.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2024 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is currently trending as a potential acquisition target following reports of takeover interest from Legendary Entertainment, fueling community speculation about a competitive bidding war. Investors are closely monitoring the company's strong content library and upcoming theatrical releases as catalysts that could drive a premium valuation in the current media consolidation landscape.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is attracting significant investor attention driven by the commercial launch of NEREUS for motion sickness and ongoing speculation regarding a potential buyout from major pharmaceutical firms. The community is actively debating the company's aggressive regulatory stance and long-term pipeline potential, with many investors viewing current price volatility as a consolidation phase before a possible acquisition.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is seeing heightened interest as investors anticipate potential ETF launches and regulatory developments, while the community remains deeply polarized over concerns regarding token dilution and the exchange's leadership. Meanwhile, the Cronos ecosystem continues to generate discussion through the rise of native meme coins like $MERY.X, which supporters view as a secure, community-driven alternative benefiting from its close correlation with the CRO network.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acumen Pharmaceuticals (ABOS) Expected to Announce Quarterly Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-acumen-pharmaceuticals-inc-stock...

Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Increases By 46.4%

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totaling 1,545,029 shares, an increase of 46.4% from the March 31st total of 1,055,415 shares. Approximately 2.4% of the...

Acumen Pharmaceuticals (NASDAQ:ABOS) Trading 0.7% Higher   - Still a Buy?

Acumen Pharmaceuticals (NASDAQ:ABOS) Shares Up 0.7% - Here's Why...

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.

Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the stock, Marketbeat Ratings...

Acumen Pharmaceuticals (NASDAQ:ABOS) Receives "Buy" Rating from BTIG Research

BTIG Research reissued a "buy" rating and issued a $8.00 target price on shares of Acumen Pharmaceuticals in a report on Thursday...

Acumen Pharmaceuticals Q4 Earnings Call Highlights

Acumen Pharmaceuticals (NASDAQ:ABOS) outlined progress across its lead Alzheimer's disease program and an emerging "enhanced brain delivery" (EBD) platform during its fourth-quarter and full-year 2025 update, while management reiterated expectations for a key Phase 2 readout later in 2026 and provid...

Acumen Pharmaceuticals (NASDAQ:ABOS) Announces Earnings Results, Beats Expectations By $0.09 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) released its earnings results on Thursday. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.09...

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Newton, MA.

Acumen Pharmaceuticals Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

ABOSAcumen Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABOS News